Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Serine/Threonine Protein Kise ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Overview
Serine/Threonine Protein Kise ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Serine/Threonine Protein Kise ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Serine/Threonine Protein Kise ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Artios Pharma Ltd
AstraZeneca Plc
Atrin Pharmaceuticals LLC
Bayer AG
Biokine Therapeutics Ltd
Cybrexa Inc
IMPACT Therapeutics Inc
Merck KGaA
Pfizer Inc
Repare Therapeutics Inc
Vertex Pharmaceuticals Inc
Serine/Threonine Protein Kise ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Drug Profiles
ATRN-119 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATRN-212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1895344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
berzosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BKT-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBX-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceralasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceralasertib + olaparib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-09 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-1774 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-4344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-3500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ATR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ATR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ATR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-821 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Serine/Threonine Protein Kise ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Dormant Products
Serine/Threonine Protein Kise ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Discontinued Products
Serine/Threonine Protein Kise ATR (Ataxia Telangiectasia And Rad3 Related Protein or FRAP Related Protein 1 or ATR or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Sep 23, 2019: Merck KGaA to announce data of M6620 at ESMO 2019 Congress
May 13, 2019: Bayer to present abstract on on investigatiol ATR inhibitor BAY 1895344 at ASCO 2019
Oct 09, 2018: Merck KGaA to announce data of M6620 at ESMO 2018 Congress
May 16, 2018: Merck’s M6620 Data at ASCO 2018 to Showcase Progress and Further Optiolity of Oncology Pipeline
Aug 30, 2017: Merck To Present Data On M6620 At ESMO 2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Artios Pharma Ltd, H1 2020
Pipeline by AstraZeneca Plc, H1 2020
Pipeline by Atrin Pharmaceuticals LLC, H1 2020
Pipeline by Bayer AG, H1 2020
Pipeline by Biokine Therapeutics Ltd, H1 2020
Pipeline by Cybrexa Inc, H1 2020
Pipeline by IMPACT Therapeutics Inc, H1 2020
Pipeline by Merck KGaA, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Repare Therapeutics Inc, H1 2020
Pipeline by Vertex Pharmaceuticals Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020